TABLE 1.
Description of study populations and concordance of positivity for 21 HPV types by E7-MPG and GP5+/6+RLB testing
| Country | Sample type | Median subject age (5%–95% range [yr]) | Na | No. (%) of samples by E7-MPG and GP5+/6+RLB resultsb |
|||
|---|---|---|---|---|---|---|---|
| +/+ | +/− | −/+ | −/− | ||||
| Bhutan | Cells | 22 (19–24) | 884 | 207 (23.4) | 107 (12.1) | 6 (0.7) | 564 (63.8) |
| Rwanda | Cells | 22 (18–24) | 1,169 | 380 (32.5) | 189 (16.2) | 7 (0.6) | 593 (50.7) |
| Mongolia | Cells | 34 (21–54) | 635 | 264 (41.6) | 177 (27.9) | 5 (0.8) | 189 (29.8) |
| Bhutan | Urine | 19 (18–38) | 1,062 | 87 (8.2) | 77 (7.3) | 5 (0.5) | 893 (84.1) |
| Rwanda | Urine | 19 (17–20) | 912 | 76 (8.3) | 80 (8.8) | 1 (0.1) | 755 (82.8) |
| Total | 4,662 | 1,014 (21.8) | 630 (13.5) | 24 (0.5) | 2,994 (64.2) | ||
a
N, number of samples.
b
+/+, positive by both tests; +/−, positive only by E7-MPG; −/+, positive only by GP5+/6+RLB; −/−, negative by both tests.